Shaobo Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shaobo Zhang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Courtney W. Houchen
Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA
8 shared publications - Gaoyuan Lv
Chinese Academy of Medical Sciences & Peking Union Medical College 1 State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Beijing, China
8 shared publications - Hao Yuan
University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
8 shared publications - Haoran Qi
Chinese Academy of Medical Sciences & Peking Union Medical College 1 State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Beijing, China
8 shared publications - Jing Han
Chinese Academy of Medical Sciences & Peking Union Medical College 1 State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Beijing, China
8 shared publications - Michael S. Bronze
Division of Infectious Diseases and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
8 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
Pancreatic cancer remains one of the deadliest malignancies, with gemcitabine-based chemotherapy as the mainstay treatment for most patients, yet resistance emerges almost universally. A defining feature of pancreatic cancer is its dense, fibroblast-rich stroma, in which heterogeneous cancer-associated fibroblasts (CAF) actively shape tumor biology and therapeutic response. Here, we elucidated a stromal–metabolic mechanism through which chemoresistant CAFs confer gemcitabine resistance. We identified a subset of mitophagy-competent CAFs that enhanced pancreatic cancer gemcitabine resistance. The epithelial–mesenchymal transition transcription factor ZEB1 acts as a master regulator of this CAF-driven chemoresistance program, being upregulated and epigenetically activated via SETD1A-mediated H3K4 methylation in gemcitabine-resistant CAFs. ZEB1 promotes BNIP3-mediated mitophagy in CAFs, leading to increased nucleotides secretion, which competitively inhibited gemcitabine incorporation into cancer cells while simultaneously supplying pyrimidine metabolism substrates for pyrimidine metabolism. Concurrently, ZEB1 transcriptionally activated CXCL8, engaging the CXCR1/2–MEK/ERK pathway in tumor cells and further augmenting pyrimidine metabolism via the RRM1/E2F1/G6PD axis, collectively diminishing gemcitabine cytotoxicity. Notably, combined inhibition of CXCR1/2 or G6PD with gemcitabine robustly suppressed tumor growth and restored chemosensitivity both in vitro and in vivo. These findings uncover a key stromal–metabolic axis in pancreatic cancer, linking mitophagy CAF activity to metabolic remodeling in tumor cells and identifying ZEB1 and its downstream network as actionable targets to overcome chemoresistance. Significance:ZEB1 reprograms mitophagy-competent CAFs to promote gemcitabine resistance by enhancing nucleotide supply and activating tumor pyrimidine metabolism, supporting therapeutic targeting of the ZEB1–CXCL8–pyrimidine axis in pancreatic cancer.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
Pancreatic cancer remains one of the deadliest malignancies, with gemcitabine-based chemotherapy as the mainstay treatment for most patients, yet resistance emerges almost universally. A defining feature of pancreatic cancer is its dense, fibroblast-rich stroma, in which heterogeneous cancer-associated fibroblasts (CAF) actively shape tumor biology and therapeutic response. Here, we elucidated a stromal–metabolic mechanism through which chemoresistant CAFs confer gemcitabine resistance. We identified a subset of mitophagy-competent CAFs that enhanced pancreatic cancer gemcitabine resistance. The epithelial–mesenchymal transition transcription factor ZEB1 acts as a master regulator of this CAF-driven chemoresistance program, being upregulated and epigenetically activated via SETD1A-mediated H3K4 methylation in gemcitabine-resistant CAFs. ZEB1 promotes BNIP3-mediated mitophagy in CAFs, leading to increased nucleotides secretion, which competitively inhibited gemcitabine incorporation into cancer cells while simultaneously supplying pyrimidine metabolism substrates for pyrimidine metabolism. Concurrently, ZEB1 transcriptionally activated CXCL8, engaging the CXCR1/2–MEK/ERK pathway in tumor cells and further augmenting pyrimidine metabolism via the RRM1/E2F1/G6PD axis, collectively diminishing gemcitabine cytotoxicity. Notably, combined inhibition of CXCR1/2 or G6PD with gemcitabine robustly suppressed tumor growth and restored chemosensitivity both in vitro and in vivo. These findings uncover a key stromal–metabolic axis in pancreatic cancer, linking mitophagy CAF activity to metabolic remodeling in tumor cells and identifying ZEB1 and its downstream network as actionable targets to overcome chemoresistance. Significance:ZEB1 reprograms mitophagy-competent CAFs to promote gemcitabine resistance by enhancing nucleotide supply and activating tumor pyrimidine metabolism, supporting therapeutic targeting of the ZEB1–CXCL8–pyrimidine axis in pancreatic cancer.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
Autophagy activated CAF is correlated with PC gemcitabine resistance
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
Autophagy activated CAF is correlated with PC gemcitabine resistance
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
CAFs-derived CXCL8 upregulates RRM1-E2F1-G6PD through MAPK pathway in pancreatic cancer
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
CAFs-derived CXCL8 upregulates RRM1-E2F1-G6PD through MAPK pathway in pancreatic cancer
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
ZEB1 facilitates autophagy of CAFs and blocking ZEB1 increased PC GEM sensitivity
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
ZEB1 facilitates autophagy of CAFs and blocking ZEB1 increased PC GEM sensitivity
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
ZEB1 enhances CAF mitophagy via BNIP3 which leads to GEM resistance in PC
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
ZEB1 enhances CAF mitophagy via BNIP3 which leads to GEM resistance in PC
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
Blocking of ZEB1 in CAFs suppresses nucleoside metabolism in PC
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
Blocking of ZEB1 in CAFs suppresses nucleoside metabolism in PC
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
CAFs-derived CXCL8 promotes PC pyrimidine metabolism and inhibits GEM activity
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
CAFs-derived CXCL8 promotes PC pyrimidine metabolism and inhibits GEM activity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
Pancreatic cancer remains one of the deadliest malignancies, with gemcitabine-based chemotherapy as the mainstay treatment for most patients, yet resistance emerges almost universally. A defining feature of pancreatic cancer is its dense, fibroblast-rich stroma, in which heterogeneous cancer-associated fibroblasts (CAF) actively shape tumor biology and therapeutic response. Here, we elucidated a stromal–metabolic mechanism through which chemoresistant CAFs confer gemcitabine resistance. We identified a subset of mitophagy-competent CAFs that enhanced pancreatic cancer gemcitabine resistance. The epithelial–mesenchymal transition transcription factor ZEB1 acts as a master regulator of this CAF-driven chemoresistance program, being upregulated and epigenetically activated via SETD1A-mediated H3K4 methylation in gemcitabine-resistant CAFs. ZEB1 promotes BNIP3-mediated mitophagy in CAFs, leading to increased nucleotides secretion, which competitively inhibited gemcitabine incorporation into cancer cells while simultaneously supplying pyrimidine metabolism substrates for pyrimidine metabolism. Concurrently, ZEB1 transcriptionally activated CXCL8, engaging the CXCR1/2–MEK/ERK pathway in tumor cells and further augmenting pyrimidine metabolism via the RRM1/E2F1/G6PD axis, collectively diminishing gemcitabine cytotoxicity. Notably, combined inhibition of CXCR1/2 or G6PD with gemcitabine robustly suppressed tumor growth and restored chemosensitivity both in vitro and in vivo. These findings uncover a key stromal–metabolic axis in pancreatic cancer, linking mitophagy CAF activity to metabolic remodeling in tumor cells and identifying ZEB1 and its downstream network as actionable targets to overcome chemoresistance. Significance: This study reveals that ZEB1 reprograms mitophagy-competent CAFs to promote gemcitabine resistance by enhancing nucleotide supply and activating tumor pyrimidine metabolism, supporting therapeutic targeting of the ZEB1–CXCL8–pyrimidine axis in pancreatic cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
Open AccessMitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer
Pancreatic cancer remains one of the deadliest malignancies, with gemcitabine-based chemotherapy as the mainstay treatment for most patients, yet resistance emerges almost universally. A defining feature of pancreatic cancer is its dense, fibroblast-rich stroma, in which heterogeneous cancer-associated fibroblasts (CAF) actively shape tumor biology and therapeutic response. Here, we elucidated a stromal–metabolic mechanism through which chemoresistant CAFs confer gemcitabine resistance. We identified a subset of mitophagy-competent CAFs that enhanced pancreatic cancer gemcitabine resistance. The epithelial–mesenchymal transition transcription factor ZEB1 acts as a master regulator of this CAF-driven chemoresistance program, being upregulated and epigenetically activated via SETD1A-mediated H3K4 methylation in gemcitabine-resistant CAFs. ZEB1 promotes BNIP3-mediated mitophagy in CAFs, leading to increased nucleotides secretion, which competitively inhibited gemcitabine incorporation into cancer cells while simultaneously supplying pyrimidine metabolism substrates for pyrimidine metabolism. Concurrently, ZEB1 transcriptionally activated CXCL8, engaging the CXCR1/2–MEK/ERK pathway in tumor cells and further augmenting pyrimidine metabolism via the RRM1/E2F1/G6PD axis, collectively diminishing gemcitabine cytotoxicity. Notably, combined inhibition of CXCR1/2 or G6PD with gemcitabine robustly suppressed tumor growth and restored chemosensitivity both in vitro and in vivo. These findings uncover a key stromal–metabolic axis in pancreatic cancer, linking mitophagy CAF activity to metabolic remodeling in tumor cells and identifying ZEB1 and its downstream network as actionable targets to overcome chemoresistance. Significance: This study reveals that ZEB1 reprograms mitophagy-competent CAFs to promote gemcitabine resistance by enhancing nucleotide supply and activating tumor pyrimidine metabolism, supporting therapeutic targeting of the ZEB1–CXCL8–pyrimidine axis in pancreatic cancer.
- 6 February 2025
- Published by Elsevier in Cancer Letters
- Vol. 614, 217523
Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer
- 6 February 2025
- Published by Elsevier in Cancer Letters
- Vol. 614, 217523
Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer
- 14 April 2022
- Published by Elsevier in Experimental Cell Research
- Vol. 416 (1) , 113158
MAFB promotes the malignant phenotypes by IGFBP6 in esophageal squamous cell carcinomas
- 14 April 2022
- Published by Elsevier in Experimental Cell Research
- Vol. 416 (1) , 113158
MAFB promotes the malignant phenotypes by IGFBP6 in esophageal squamous cell carcinomas